Global Cerebral Palsy Treatment Market Report to 2030 - Featuring Merz Pharmaceuticals, Pfizer, Bayer and Johnson & Johnson Among Others

·7 min read
Company Logo
Company Logo

Global Cerebral Palsy Treatment Market

Global Cerebral Palsy Treatment Market
Global Cerebral Palsy Treatment Market

Dublin, May 16, 2022 (GLOBE NEWSWIRE) -- The "Cerebral Palsy Treatment Market by Drug Type, Disease Type, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The global cerebral palsy treatment market was valued at $3166.82 million in 2020, and is projected to reach $4,365.01 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.

Cerebral palsy is a group of disorders that affect a person's ability to move and maintain balance and posture. Cerebral palsy is the most common motor disability in childhood. Cerebral palsy is caused by abnormal brain development or damage to the developing brain that affects a person's ability to control his or her muscles.

Patients suffering from cerebral palsy require lifelong care with a medical care team. Although there is no cure for cerebral palsy there are various treatments like medications, therapies, surgical procedures and other treatments. Medications include muscle or nerve injections, and oral muscle relaxants. Major therapies include physical therapies, occupational therapies, speech and language therapies and recreational therapies.

The factors that drive the growth of the global cerebral palsy treatment market include upsurge in the prevalence of cerebral palsy, rising focus on the healthcare technological advancements coupled with growing availability of newer cerebral palsy drugs, increasing research and development proficiencies, government initiatives to promote the awareness and increasing reliance on medications are the major factors prevailing the growth of the global cerebral palsy treatment market.

However, high costs associated with medications is expected to create hindrances for the growth of the cerebral palsy treatment market. Moreover, Side effects associated with the medications such as drowsiness, depression, headaches, lethargy, confusion, and dizziness and lack of awareness in the backward and underdeveloped economies are causing hurdles in the cerebral palsy treatment market.

Various initiatives have been taken by the government to encourage the regulatory affairs in getting approvals for novel drugs, and insurance policies which are creating lucrative opportunities in the cerebral palsy treatment market.

The report segments the market based on drug type, disease type, distribution channel, and region. Based on drug type, it is classified into anticholinergics, anticonvulsants, antidepressants, and others. Based on disease type, it is classified into spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy. Based on distribution channel, the market is divided into hospital pharmacies, retail stores and pharmacies, and online providers. Based on the region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Region wise, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the cerebral palsy treatment market in 2020, and is expected to retain its dominance throughout the forecast period. This is primarily attributed to significant rise in investments as well as partnerships and collaborations.

Business expansions is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global cerebral palsy treatment market. The key companies profiled in the report include Merz Pharmaceuticals, LLC., Pfizer Inc., Teva Pharmaceuticals, Bayer AG, Johnson & Johnson, GlaxoSmithKline plc., Novartis, AbbVie Inc., Par Pharmaceutical, Allergan plc., Lannett Company, Inc.

Key Benefits

  • The report provides in-depth analysis of the global Cerebral Palsy Treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets

  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market

  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities

  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Cerebral Palsy Treatment market growth

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter'S Five Force Analysis
3.4. Top Player Positioning, 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Increase in Incidences of Cerebral Palsy
3.5.1.2. Rise in Investments by Key Player
3.5.2. Restraint
3.5.2.1. Side Effects Associated With Drugs
3.5.3. Opportunity
3.5.3.1. Initiatives by Governments for Regulatory Approvals
3.6. Covid-19 Impact Analysis on Cerebral Palsy Treatment Market

Chapter 4: Cerebral Palsy Treatment Market, by Drug Type
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Anticholinergics
4.2.1. Market Size and Forecast, by Region
4.2.2. Market Analysis, by Country
4.3. Anticonvulsants
4.3.1. Market Size and Forecast, by Region
4.3.2. Market Analysis, by Country
4.4. Antidepressants
4.4.1. Market Size and Forecast, by Region
4.4.2. Market Analysis, by Country
4.5. Others
4.5.1. Market Size and Forecast, by Region
4.5.2. Market Analysis, by Country

Chapter 5: Cerebral Palsy Treatment Market, by Disease Type
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Spastic Cerebral Palsy
5.2.1. Market Size and Forecast, by Region
5.2.2. Market Analysis, by Country
5.3. Dyskinetic Cerebral Palsy
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Analysis, by Country
5.4. Ataxic Cerebral Palsy
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Analysis, by Country
5.5. Mixed Cerebral Palsy
5.5.1. Market Size and Forecast, by Region
5.5.2. Market Analysis, by Country

Chapter 6: Cerebral Palsy Treatment Market, by Distribution Channel
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Hospital Pharmacy
6.2.1. Market Size and Forecast, by Region
6.2.2. Market Analysis, by Country
6.3. Retail Store and Pharmacy
6.3.1. Market Size and Forecast, by Region
6.3.2. Market Analysis, by Country
6.4. Online Providers
6.4.1. Market Size and Forecast, by Region
6.4.2. Market Analysis, by Country

Chapter 7: Cerebral Palsy Treatment Market, by Region

Chapter 8: Company Profiles
8.1. Abbvie Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves and Developments
8.2. Bayer AG
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.3. GlaxoSmithKline plc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Johnson and Johnson
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves and Developments
8.5. Lannett Company, Inc.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves and Developments
8.6. Merz Pharmaceuticals, LLC.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Key Strategic Moves and Developments
8.7. Novartis
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Par Pharmaceuticals
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.9. Pfizer, Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Teva Pharmaceutical Industries Limited.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance

For more information about this report visit https://www.researchandmarkets.com/r/yqt38e

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting